COMPARATIVE PHARMACOLOGY AND CLINICAL RESPONSES TO METAHEXAMIDE *

doi:10.1111/j.1749-6632.1959.tb44934.x

Paper

COMPARATIVE PHARMACOLOGY AND CLINICAL RESPONSES TO METAHEXAMIDE *

Published Sep 1, 1959 · G. Hamwi, T. G. Skillman, F. Kruger

Annals of the New York Academy of Sciences

Q1 SJR score

4

Citations

0

Influential Citations

Full text

Semantic Scholar

Abstract

RIetahexamide (N-(3 amino-4-methyl benzine-sulfony1)-N1-cyclohexylurea) was studied for the purpose of comparing its hypoglycemic potency, toxicity, and pharmacology with the currently existing compounds used for oral therapy of diabetes. Observations made during a 6-month period in which metahexamide was given in daily doses ranging from SO to 500 mg./day to 73 maturity-onset diabetic patients permit the conclusion that this compound embodies a hypoglycemic potency that is approximately 7 times that of tolbutamide and twice that of chlorpropamide. In addition, normoglycemia is obtained in responsive patients with serum concentrations of metahexamide that range from one fifth to one third as high as the levels needed with the other sulfonylureas. Early studies of the incidence of untoward reactions to metahexamide indicate an incidence of about 10 per cent. This incidence is comparable to that of chlorpropamide. However, preliminary data suggest that alterations of liver function are more frequent with metahexamide than with other compounds.

Non-RCT

Study Snapshot

Key takeawayMetahexamide has a hypoglycemic potency 7 times that of tolbutamide and twice that of chlorpropamide, with a similar incidence of adverse reactions but more frequent liver function alterations.

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

COMPARATIVE PHARMACOLOGY AND CLINICAL RESPONSES TO METAHEXAMIDE *

References

Citations